Publications, regulatory files, certifications, technical documents, patents, trademarks and business materials are organized for direct review. Human clinical-study documents are available to qualified B2B partners on request.
Product brochures and buyer-facing materials.
4Current English trade-show brochure presenting the AMPK-ON™ Platform, three benefit territories, mechanism, target applications, product specifications, certifications and partner information.
Buyer-facing executive summary covering product positioning, body-fat and joint clinical evidence, AMPK mechanism, ingredient specifications, formulation options and regulatory readiness. Detailed clinical reports are available under NDA.
Global B2B platform presentation covering Actiponin® technology, body-fat and joint-health clinical pillars, formulation opportunities and the future metabolic-health roadmap.
Korean-language product and ingredient brochure.
Peer-reviewed papers and scientific publications.
4Peer-reviewed research identifying Damulin A and Damulin B as novel dammarane-type saponins from Gynostemma pentaphyllum and investigating their AMPK-related activity in cultured L6 myotube cells.
Preclinical research examining heat-processed Gynostemma pentaphyllum extract (Actiponin) in cellular and ob/ob mouse models, including AMPK activation, fat oxidation and glucose uptake.
Peer-reviewed in vitro and in vivo osteoarthritis research evaluating Actiponin and its components Damulin A and Damulin B in cartilage breakdown and chondroprotection-related models.
Peer-reviewed research investigating Actiponin, Damulin A and Damulin B in inflammatory signaling using RAW264.7 cells and carrageenan-induced rat models.
Human clinical studies, reports and source-derived clinical summaries.
3A 12-week randomized, double-blind, placebo-controlled human trial in 80 participants evaluating Actiponin at 450 mg/day for body weight, body fat and abdominal fat-related outcomes.
English analytical summary focused on total cholesterol and LDL cholesterol findings from a 12-week randomized, double-blind, placebo-controlled human clinical trial of Dungkulcha Ethanol Extract.
Buyer-facing summary of a 12-week randomized, double-blind, placebo-controlled human study evaluating knee-joint comfort and function in 150 participants.
Government recognition and regulatory correspondence.
2Korean functional ingredient recognition documentation for Actiponin® / ethanol-extracted powder of Gynostemma pentaphyllum leaf.
FDA correspondence concerning the NDI notification for Gynostemma pentaphyllum extract marketed under the trade name Actiponin®.
Third-party certification documents.
2Korea Muslim Federation Halal Committee certificate for Actiponin® (Gynostemma pentaphyllum extract), valid until October 30, 2028.
Vegan certification for Actiponin®, certification period November 21, 2024 through November 20, 2027.
Specifications, batch quality and safety documents.
4Certificate of Analysis for batch ADN2602, including organoleptic, physicochemical, heavy-metal, microbiological and Damulin A results.
Product specification covering botanical identity, Damulin A standardization, physical properties, heavy metals and microbiological specifications.
Safety Data Sheet covering product identification, composition, hazards, handling, storage and toxicological information.
Current TDS covering product identity, Damulin A specification, quality limits, certifications, recommended applications, packaging, storage and 24-month shelf life.
Patent and trademark documentation.
12Korean manufacturing patent covering a preparation method for a Gynostemma extract enriched in Damulin A and Damulin B and related compositions.
United States patent certificate for the Actiponin-related manufacturing invention.
Chinese invention patent covering preparation of a Gynostemma extract enriched in Damulin A/B and related compositions.
Japanese patent certificate covering Gynostemma extract compositions containing Damulin A and Damulin B.
Korean trademark registration for ACTIPONIN.
United States federal trademark registration for ACTIPONIN, Reg. No. 4,476,763.
WIPO Madrid international registration No. 1 833 340, registered September 23, 2024.
UKIPO statement granting protection to international registration 1833340 for ACTIPONIN.
EUIPO statement granting protection to international registration 1833340 for ACTIPONIN.
JPO statement granting protection to international registration 1833340 for ACTIPONIN.
CNIPA statement granting protection to international registration 1833340 for ACTIPONIN.
IP Australia total grant of protection for international registration 1833340, Australian Trade Mark No. 2512512.
Industry recognition related to finished products using Actiponin®.
1WholeFoods Magazine Natural Choice Awards feature for Life Extension AMPK Metabolic Activator, a finished product formulated with Actiponin®.